Pro-inflammatory CXCL-10, TNF-α, IL-1β, and IL-6: biomarkers of SARS-CoV-2 infection (original) (raw)

Abstract

Currently, the world is witnessing the pandemic of COVID-19, a disease caused by the novel coronavirus SARS-CoV-2. Reported differences in clinical manifestations and outcomes in SARS-CoV-2 infection could be attributed to factors such as virus replication, infiltration of inflammatory cells, and altered cytokine production. Virus-induced aberrant and excessive cytokine production has been linked to the morbidity and mortality of several viral infections. Using a Luminex platform, we investigated plasma cytokine and chemokine levels of 27 analytes from hospitalized asymptomatic (n = 39) and mildly symptomatic (n = 35) SARS-CoV-2-infected patients (in the early phase of infection), recovered individuals (45-60 days postinfection) (n = 40), and uninfected controls (n = 36) from the city of Pune located in the state of Maharashtra in India. Levels of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α and the chemokine CXCL-10 were significantly higher, while those of the antiviral cytokines IFN-γ and IL-12 p70 were significantly lower in both asymptomatic and mildly symptomatic patients than in controls. Comparison among the patient categories revealed no difference in the levels of the cytokines/ chemokines except for CXCL-10 being significantly higher and IL-17, IL-4, and VEGF being significantly lower in the mildly symptomatic patients. Interestingly, levels of all key analytes were significantly lower in recovered individuals than in those in both patient categories. Nevertheless, the level of CXCL10 was significantly higher in the recovered patients than in the controls, indicating that the immune system of SARS-CoV-2 patients may take a longer time to normalize. Our data suggest that IL-6, IL-1β, TNF-α, CXCL-10, and reduced antiviral cytokines could be used as biomarkers of SARS-CoV-2 infection. Abbreviations SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 CRS Cytokine release syndrome MERS-CoV Middle East respiratory syndrome coronavirus ACE2 Angiotensin-converting enzyme 2 ARDS Acute respiratory distress syndrome RT-PCR Reverse transcription polymerase chain reaction COVID-19 Coronavirus disease 2019 ROC Receiver operating characteristic curve Handling Editor: Zhenhai Chen. Siddhesh Vishwakarma and Diptee Trimbake contributed equally.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (27)

  1. Coperchini F et al (2020) The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev 53:25-32
  2. Soy M et al (2020) Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 39(7):2085-2094
  3. Long QX et al (2020) Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 26(8):1200-1204
  4. Conti P et al (2020) Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 34(2):327-331
  5. Chi Y et al (2020) Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China. J Infect Dis 222(5):746-754
  6. Pons S et al (2020) The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care 24(1):353
  7. Zhou Z et al (2020) Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe 27(6):883-890
  8. Xiong Y et al (2020) Transcriptomic characteristics of bronchoalve- olar lavage fluid and peripheral blood mononuclear cells in COVID- 19 patients. Emerg Microbes Infect 9(1):761-770
  9. Barilla F et al (2020) Focus on clinical practice: angiotensin- converting enzyme 2 and corona virus disease 2019: pathophysi- ology and clinical implications. J Cardiovasc Med (Hagerstown) 21(9):630-633
  10. Wu D, Yang XO (2020) TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor fedratinib. J Microbiol Immunol Infect 53(3):368-370
  11. Potdar V et al (2020) Genomic analysis of SARS-CoV-2 strains among Indians returning from Italy, Iran & China, & Italian tourists in India. Indian J Med Res 151(2 & 3):255-260
  12. Arankalle VA et al (2010) Role of host immune response and viral load in the differential outcome of pandemic H1N1 influenza virus infection in Indian patients. PLoS One 5(10):e13099
  13. Tripathy AS et al (2011) Epidemic of hepatitis B with high mortal- ity in India: association of fulminant disease with lack of CCL4 and natural killer T cells. J Viral Hepat 18(10):e415-e422
  14. Potdar V et al (2020) Respiratory virus detection among the overseas returnees during the early phase of COVID-19 pandemic in India. Indian J Med Res 151(5):486-489
  15. Alhetheel A et al (2020) Assessment of Th1/Th2 cytokines among patients with Middle East respiratory syndrome coronavirus infec- tion. Int Immunol 32(12):799-804
  16. Chatterjee SK, Saha S, Munoz MNM (2020) Molecular pathogen- esis, immunopathogenesis and novel therapeutic strategy against COVID-19. Front Mol Biosci 7:196
  17. Shirazi J et al (2020) Significant unresolved questions and opportu- nities for bioengineering in understanding and treating COVID-19 disease progression. Cell Mol Bioeng 13(4):1-26
  18. Leisman DE et al (2020) Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and com- parison with other inflammatory syndromes. Lancet Respir Med 8(12):1233-1244
  19. Zhang C et al (2020) Cytokine release syndrome in severe COVID- 19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 55(5):105954
  20. Liu B et al (2020) Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun 22351-22356
  21. Jiang Y et al (2005) Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med 171(8):850-857
  22. Kim ES et al (2016) Clinical progression and cytokine profiles of middle east respiratory syndrome coronavirus infection. J Korean Med Sci 31(11):1717-1725
  23. Chen Y et al (2020) IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Mol Med 26(1):1-12
  24. Costela-Ruiz VJ et al (2020) SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev 54:62-75
  25. Huang KJ et al (2005) An interferon-gamma-related cytokine storm in SARS patients. J Med Virol 75(2):185-194
  26. Wong CK et al (2004) Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immu- nol 136(1):95-103
  27. Xiong X et al (2020) Haematological and immunological data of Chinese children infected with coronavirus disease 2019. Data Brief 31:105953